Dear Shareholders,
We are delighted to provide an update on progress at MindBio, as we head into the second half of 2024 and continue with dosing in multiple Phase 2B clinical trials and we advance the Company closer towards its commercialisation objective.
The Company is pleased to report on its two currently dosing Phase 2B clinical trials which include assessing MB22001, MindBio's lead candidate drug in treating the following conditions:
| Major Depressive Disorder: The trial is assessing MB22001 on 90 patients with Major Depressive Disorder with 45 patients randomized to the placebo group and 45 patients to the MB22001 intervention group in a triple dummy, active placebo controlled clinical trial. | ||
| 2. | Advanced Stage Cancer - End of Life Distress related Depression and Anxiety: The trial is assessing MB22001 on 40 patients with advanced stage cancer, with 20 patients randomized to the placebo group and 20 patients to the MB22001 intervention group in a double blind, placebo controlled clinical trial. | |
| MindBio has fully funded and paid in advance for these two Phase 2B clinical trials. Dosing is progressing as scheduled with recruiting of patients and initiation to take-home dosing in both trials progressing positively and both trials due for completion in 2025. | ||
| MindBio has a third Phase 2B clinical trial that has been approved to start dosing: | ||
| 3. | Pre-Menstrual Syndrome & Pre-Menstrual Dysphoric Disorder - The trial will initially gather baseline data from healthy menstruating persons in a Phase 1/2a trial administering MB22001 during the luteal phase of the menstrual cycle. The trial will lead into a much larger randomized controlled trial in patients with Pre-Menstrual Syndrome and Pre-Menstrual Dysphoric Disorder. | |
MindBio Leads Global Public Companies in Non-hallucinogenic Psychedelic Clinical Trials
MindBio is the only publicly listed company in the world specializing in a scalable psychedelic microdosing treatment model that is sub-hallucinogenic...
株主の皆様へ
MindBioの進捗状況について報告できて嬉しいです。2024年下半期に入って、複数の第20相臨床試験での投薬を続け、会社を商業化目標により近づけています。
会社は、MB22001を評価する...